Inclusion Criteria:

- Patients must have histologically or cytologically confirmed malignancy which is
metastatic or unresectable and for which standard curative or palliative measures do
not exist or are no longer effective

- There is no limit on prior therapies

- ECOG performance status 0-2

- Leukocytes >= 3,000/ul

- Absolute neutrophil count >= 1,500/ul

- Platelets >= 100,000/ul

- Total bilirubin =< 1.5 mg/dL

- AST (SGOT)/ALT (SGPT) =< 2.5 x institutional upper limit of normal

- Creatinine clearance >= 50 mL/min as calculated by the Cockroft-Gault formula

- Patients with no >= grade 2 (CTC 2.0) neuropathy

- The effects of oxaliplatin on the developing human fetus at the recommended
therapeutic dose are unknown; for this reason and because DNA alkylating agents are
known to be teratogenic, women of child-bearing potential and men must agree to use
adequate contraception (hormonal or barrier method of birth control) prior to study
entry and for the duration of study participation; should a woman become pregnant or
suspect she is pregnant while participating in this study, she should inform her
treating physician immediately

- Because the risk of toxicity in nursing infants secondary to oxaliplatin treatment of
the mother is unknown but may be harmful, breastfeeding should be discontinued if the
mother is treated with oxaliplatin

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
the study

- Patients undergoing therapy with other investigational agents

- Patients with known brain metastases should be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive neurologic
dysfunction that would confound the evaluation of neurologic and other toxicities

- History of allergy to platinum compounds or to antiemetics appropriate for
administration in conjunction with protocol-directed chemotherapy

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, or unstable angina pectoris, or
cardiac arrhythmia

- Pregnant and nursing women are excluded from this study because oxaliplatin is a DNA
alkylating agent with the potential for teratogenic or abortifacient effects

- HIV-positive patients receiving anti-retroviral therapy (HAART) are excluded from the
study because of possible pharmacokinetic interactions